Skip to main content

Oncometabolitic control of tumor growth and epileptogenesis in IDH mutated gliomas: D2HG signaling mechanism.

Project description

Metabolic control of tumour growth and epileptogenesis: the case of gliomas

Gliomas may present with mutations in the isocitrate dehydrogenase (IDH) gene, which lead to the overproduction of the oncometabolite D-2-hydroxyglutarate (D2HG). D2HG is thought to participate in both epileptogenic and oncologic processes, modulating the excitatory neurotransmitter glutamate. The scope of the EU-funded GliomaSignals project is to investigate the role of D2HG in the neurobiology of gliomas and elucidate the mechanism by which it modulates, via its effects on glutamatergic signalling, tumour growth and epilepsy processes. The project's results are expected to shed light on the high epileptic activity associated with glioma tumour invasion and unveil novel targets for therapy.

Host institution

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
Net EU contribution
€ 1 875 135,00
Address
Rue De Tolbiac 101
75654 Paris
France

See on map

Region
Ile-de-France Ile-de-France Paris
Activity type
Research Organisations
Other funding
€ 1 875 135,00

Beneficiaries (1)

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
France
Net EU contribution
€ 1 875 135,00
Address
Rue De Tolbiac 101
75654 Paris

See on map

Region
Ile-de-France Ile-de-France Paris
Activity type
Research Organisations
Other funding
€ 1 875 135,00